Artivion Inc. (AORT)
24.25
-0.25 (-1.02%)
At close: Mar 28, 2025, 3:59 PM
24.25
0.00%
After-hours: Mar 28, 2025, 05:05 PM EDT
-1.02% (1D)
Bid | 23.06 |
Market Cap | 1.02B |
Revenue (ttm) | 390.08M |
Net Income (ttm) | -13.41M |
EPS (ttm) | -0.32 |
PE Ratio (ttm) | -75.78 |
Forward PE | 65.35 |
Analyst | Buy |
Ask | 25.68 |
Volume | 215,109 |
Avg. Volume (20D) | 432,043 |
Open | 24.71 |
Previous Close | 24.50 |
Day's Range | 23.96 - 24.62 |
52-Week Range | 19.36 - 32.33 |
Beta | 1.79 |
About AORT
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems fo...
Industry Medical - Devices
Sector Healthcare
IPO Date Feb 12, 1993
Employees 1,600
Stock Exchange NYSE
Ticker Symbol AORT
Website https://artivion.com
Analyst Forecast
According to 6 analyst ratings, the average rating for AORT stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 31.96% from the latest price.
Stock ForecastsNext Earnings Release
Artivion Inc. is scheduled to release its earnings on May 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-8.22%
Artivion shares are trading lower after the compan...
Unlock content with
Pro Subscription
10 months ago
+12.81%
Artivion shares are trading higher after the company reported a Q1 earnings beat and raised the bottom end of its FY24 guidance range.